SCHEMBL759444

SCHEMBL759444

CS(=O)(=O)SCCS(=O)(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.50
SLC6A4 P31645 1/20 0.46
PTGS1 P23219 1/20 0.38
PDE4A P27815 1/20 0.38
LMNA P02545 1/20 0.38
SLC6A6 P31641 1/20 0.38
CYP2C19 P33261 1/20 0.38
BLM P54132 1/20 0.38
HDAC3 O15379 2/20 0.37
HDAC4 P56524 2/20 0.37
HDAC1 Q13547 2/20 0.37
HDAC7 Q8WUI4 2/20 0.37
HDAC2 Q92769 2/20 0.37
HDAC10 Q969S8 2/20 0.37
HDAC11 Q96DB2 2/20 0.37
HDAC8 Q9BY41 2/20 0.37
HDAC6 Q9UBN7 2/20 0.37
HDAC9 Q9UKV0 2/20 0.37
HDAC5 Q9UQL6 2/20 0.37
APP P05067 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7668593 0.78 PTGS1 (0.41) PTGS1PDE4ALMNASLC6A6CYP2C19
SCHEMBL14651687 0.76 TRPA1 (0.67) TRPA1SLC6A4HDAC3HDAC4HDAC1
SCHEMBL933056 0.72
SCHEMBL84504 0.72
SCHEMBL29624242 0.72 TRPA1 (0.48) TRPA1SLC6A4LMNAHDAC3HDAC4
SCHEMBL13863427 0.71 LMNA (0.45) PTGS1PDE4ALMNASLC6A6CYP2C19
2,2'-Dithiodiethanesulfonic Acid SCHEMBL773704 0.71 PTGS1 (0.45) PTGS1PDE4ALMNASLC6A6CYP2C19
SCHEMBL8460647 0.70
2,2'-Dithiodiethanesulfonic Acid SCHEMBL8403166 0.69 PTGS1 (0.43) PTGS1PDE4ALMNASLC6A6CYP2C19
SCHEMBL11604930 0.69 TRPA1 (0.57) TRPA1SLC6A4HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1998057538-A1 COMPLETE ACTIVATION OF MAMMALIAN OOCYTES THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 1998-12-23 WO claimed
US-12527305-B2 Porcine reproductive and respiratory syndrome virus resistant animals THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 2026-01-20 US disclosed
US-10676538-B2 Inhibitors of Staphylococcus pseudintermedius sortase KANIA STEPHEN ANTHONY (US) 2020-06-09 US disclosed
US-20190241675-A1 Inhibitors of Staphylococcus pseudintermedius Sortase BEMIS DAVID (US) 2019-08-08 US disclosed
EP-2167531-B1 STREPTOCOCCUS PNEUMONIAE PILUS ANTIGENS NOVARTIS AG (CH) 2012-03-21 EP disclosed
US-20110275132-A1 PURIFICATION OF BACTERIAL ANTIGENS NOVARTIS AG (CH) 2011-11-10 US disclosed
US-20110097360-A1 STREPTOCOCCUS PNEUMONIAE PILUS ANTIGENS NOVARTIS AG (CH) 2011-04-28 US disclosed
US-7829117-B2 Compounds and methods for reducing undesired toxicity of chemotherapeutic agents BIONUMERIK PHARMACEUTICALS, INC. (US) 2010-11-09 US disclosed
US-7829540-B2 Compounds and methods for reducing undesired toxicity of chemotherapeutic agents BIONUMERIK PHARMACEUTICALS, INC. (US) 2010-11-09 US disclosed
US-7829539-B2 Heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium BIONUMERIK PHARMACEUTICALS, INC. (US) 2010-11-09 US disclosed
US-20050272677-A1 Delivery of a substance to a pre-determined site APPLIED NANOSYSTEMS B.V. (NL) 2005-12-08 US disclosed
EP-1490028-A1 DELIVERY OF A SUBSTANCE TO A PRE-DETERMINED SITE Applied NanoSystems B.V. (NL) 2004-12-29 EP disclosed
EP-1397123-A2 DELIVERY OF SMALL HYDROPHILIC MOLECULES PACKAGED INTO LIPID VESICLES Applied NanoSystems B.V. (NL) 2004-03-17 EP disclosed
WO-2003084508-A1 DELIVERY OF A SUBSTANCE TO A PRE-DETERMINED SITE APPLIED NANOSYSTEMS B.V. (NL) 2003-10-16 WO disclosed
EP-1350507-A1 Delivery of a substance to a pre-determinated site Applied NanoSystems B.V. (NL) 2003-10-08 EP disclosed
US-20030118636-A1 Delivery of small hydrophilic molecules packaged into lipid vesicles APPLIED NANOSYSTEMS B.V. (NL) 2003-06-26 US disclosed
WO-2003000233-A2 DELIVERY OF SMALL HYDROPHILIC MOLECULES PACKAGED INTO LIPID VESICLES APPLIED NANOSYSTEMS B.V. (NL) 2003-01-03 WO disclosed
EP-1269993-A1 Delivery of small hydrophilic molecules packaged into lipid vesicles Applied NanoSystems B.V. (NL) 2003-01-02 EP disclosed
US-20020128203-A1 Methods of identifying inhibitory compounds and uses thereof UNIVERSITE DE LAUSANNE (CH) 2002-09-12 US disclosed
WO-2002024177-A2 METHODS OF IDENTIFYING INHIBITORY COMPOUNDS AND USES THEREOF UNIVERSITY OF LAUSANNE (CH) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030118636-A1 Delivery of small hydrophilic molecules packaged into lipid vesicles CHMP4B, SCAMP2, SLC47A2 TRPA1 457/4885SLC6A4 1001/4885PTGS1 2147/4885
US-20050272677-A1 Delivery of a substance to a pre-determined site TACR1, TACR2, NPSR1 TRPA1 1907/4885SLC6A4 56/4885PTGS1 749/4885
US-12527305-B2 Porcine reproductive and respiratory syndrome virus resistant animals PIGS, ZFR, ZP1 TRPA1 3005/4885SLC6A4 1397/4885PTGS1 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.